Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials

Cancer Immunity

Volumn 10, Issue , 2010, Pages

  Wolchok, Jedd D ^a   Weber, Jeffrey S ^b   Hamid, Omid ^c   Lebbé, Celeste ^d   Maio, Michele ^e   Schadendorf, Dirk ^f   de Pril, Veerle ^g   Heller, Kevin ^g   Chen, Tai Tsang ^g   Ibrahim, Ramy ^g   Hoos, Axel ^g   O'Day, Steven J ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Angeles Clinic and Research Institute   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Clinical trial; HLA; Ipilimumab; Melanoma; Treatment outcome

Indexed keywords

BUDESONIDE; GLYCOPROTEIN GP 100; HLA ANTIGEN; IPILIMUMAB; PLACEBO;

ADVANCED CANCER; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL DISEASE; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNE DEFICIENCY; LIVER DISEASE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 78650439466     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363: 711-723.
2. Schmidt H, Hamid O, Nissan A, Guida M, Aamdal S, Hansson J, Ridolfi R, Berman D, Chasalow SD. Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma [abstract]. Eur J Cancer Suppl 2009; 7: 577.
3. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipili-mumab monotherapy in patients with pretreated advanced mela-noma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
4. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1717.
5. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A random-ized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable Stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598.
6. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681- 6688.
7. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunoge-netics 1999; 50: 201-212.
8. Fernandez-Viña MA, Falco M, Sun Y, Stastny P. DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. Hum Immu-nol 1992; 33: 163-173.
9. Krausa P, Brywka M 3rd, Savage D, Hui KM, Bunce M, Ngai JL, Teo DL, Ong YW, Barouch D, Allsop CE, Hill AVS, McMichael AJ, Bod-mer JG, Browning MJ. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995; 45: 223-231.
10. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosen-berg SA. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lympho-cyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
11. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentru-ber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100: 8372-8377.
12. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic mela-noma and renal cancer. J Immunother 2005; 28: 593-598.
13. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289.
14. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosen-berg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysi-tis. J Immunother 2007; 30: 825-830.
15. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to deter-mine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
16. Marincola FM, Shamamian P, Rivoltini L, Salgaller M, Cormier J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR. HLA associations in the antitumor response against malignant mela-noma. J Immunother Emphasis Tumor Immunol 1995; 18: 242-252.
17. Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin- 2 (IL-2). Melanoma Res 1994; 4: 191-194.
18. Fensterle J, Trefzer U, Berger T, Andersen MH, Ugure S, Becker JC. HLA-B8 association with late-stage melanoma - an immunological lesson? BMC Medicine 2006; 4: 5.
19. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol 2002; 9: 587-593.
20. Jager MJ, Volker-Dieben HJ, De Wolffrouendaal D, Kakebeeke- Kemme H, D'Amaro J. Possible relation between HLA and ABO type and prognosis of uveal melanoma. Doc Ophthalmol 1992; 82: 43-47.
21. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
22. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant inter-feron. Cancer 2010; 116: 4326-4333.